Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MRG003 in Advanced Biliary Tract Cancer
NCT04838964Phase 2Completed
- Sponsor
- Lepu Biopharma Co., Ltd.
- Start
- May 2021
- Primary completion
- Oct 2022
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs)
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of becotatug vedotin in biliary tract cancer (BTC), sponsored by Lepu Biopharma Co., Ltd. Primary endpoint: Objective Response Rate by Independent Review Committee up to 12 months. Started May 2021; status: completed.
02
Drugs
becotatug vedotin
03
Conditions
biliary tract cancer (BTC)
Beyond the preview
Go deeper on NCT04838964.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04838964.